Life Sciences Practice: Sidley Austin

Law360, New York (August 20, 2008, 12:00 AM EDT) -- With the escalating price of health care, pharmaceutical companies are facing increased scrutiny, especially as states have started teaming up with the members of the plaintiffs bar, said leaders of Sidley Austin LLP's life sciences practice.

“Drug companies have very deep pockets, and they aren't terribly popular. They tend to get wrongly lumped in with tobacco companies as business that make harmful products,” said Paul Kalb, head of the firm’s national health care group, explaining why drug companies have become popular enforcement and litigation targets....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.